Based on the present network meta-analysis, we can conclude that mTOR inhibitor- and CDK4/6 inhibitor-based regimens demonstrated superior clinical efficacy and comparable safety profiles as second-line treatment in patients with HR-positive, HER2-negative advanced breast cancer compared to PI3K inhibitors and HDAC inhibitors. The gene discussed is HDAC9; the disease is breast carcinoma.